Concepedia

Gerald E. Hall

GE

10

Publications

736

Citations

10

H-Index

1993

Active since

Affiliations

Eli Lilly (United States)(Current)

Janssen (Belgium)

Johnson & Johnson (Sweden)

North Carolina State University

Gerald E. Hall is an author at Eli Lilly (United States) specializing in medicine, immunology, and tumor immunology.

Top concepts

Publications per year

1993–2022

10

Publications

10

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

Rikke Holmgaard, David Schaer, Yanxia Li et al. · Journal for ImmunoTherapy of Cancer · 2018 · 358 citations · Full text

The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy

David Schaer, Sandaruwan Geeganage, Nelusha Amaladas et al. · Clinical Cancer Research · 2019 · 121 citations

The β‐phaseolin gene is flanked by matrix attachment regions

A. H. M. van der Geest, Gerald E. Hall, Steven Spiker et al. · The Plant Journal · 1994 · 81 citations · Full text

, , +16

Characterization of Randomly-Obtained Matrix Attachment Regions (MARs) from Higher Plants<sup>,</sup>

Susan Michalowski, George C. Allen, Gerald E. Hall et al. · Biochemistry · 1999 · 44 citations

Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054

Yiwen Li, Carmine Carpenito, George Wang et al. · Journal for ImmunoTherapy of Cancer · 2018 · 30 citations · Full text

Rows per page

1–5 of 10